RU2008143545A - Применение антагониста рецептора ат-1 или модулятора рецептора ат-2 для лечения болезней, связанных с увеличением содержания рецепторов ат-1 или ат-2 - Google Patents
Применение антагониста рецептора ат-1 или модулятора рецептора ат-2 для лечения болезней, связанных с увеличением содержания рецепторов ат-1 или ат-2 Download PDFInfo
- Publication number
- RU2008143545A RU2008143545A RU2008143545/15A RU2008143545A RU2008143545A RU 2008143545 A RU2008143545 A RU 2008143545A RU 2008143545/15 A RU2008143545/15 A RU 2008143545/15A RU 2008143545 A RU2008143545 A RU 2008143545A RU 2008143545 A RU2008143545 A RU 2008143545A
- Authority
- RU
- Russia
- Prior art keywords
- compressed tablet
- tablet according
- microcrystalline cellulose
- receptors
- increasing
- Prior art date
Links
- 239000002333 angiotensin II receptor antagonist Substances 0.000 title 1
- 239000000400 angiotensin II type 1 receptor blocker Substances 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 229940075993 receptor modulator Drugs 0.000 title 1
- 239000007891 compressed tablet Substances 0.000 claims abstract 14
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims abstract 8
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims abstract 8
- 239000008108 microcrystalline cellulose Substances 0.000 claims abstract 8
- 229940016286 microcrystalline cellulose Drugs 0.000 claims abstract 8
- 239000004072 C09CA03 - Valsartan Substances 0.000 claims abstract 6
- SJSNUMAYCRRIOM-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SJSNUMAYCRRIOM-QFIPXVFZSA-N 0.000 claims abstract 6
- 229960004699 valsartan Drugs 0.000 claims abstract 6
- 239000013543 active substance Substances 0.000 claims abstract 4
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims abstract 2
- 239000008358 core component Substances 0.000 claims abstract 2
- 229960000913 crospovidone Drugs 0.000 claims abstract 2
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims abstract 2
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims abstract 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
1. Спрессованная таблетка, включающая валсартан в качестве действующего вещества и от 31 до 65% микрокристаллической целлюлозы в пересчете на общую массу компонентов ядра этой спрессованной таблетки. ! 2. Спрессованная таблетка по п.1, включающая от 50 до 65% микрокристаллической целлюлозы в пересчете на общую массу. ! 3. Спрессованная таблетка по п.1, включающая 50% микрокристаллической целлюлозы в пересчете на общую массу. ! 4. Спрессованная таблетка по любому из пп.1-3, включающая менее 13 мас.% кросповидона. ! 5. Спрессованная таблетка по любому из пп.1-3, в которой массовое отношение валсартана к микрокристаллической целлюлозе составляет от 2:1 до 1:1. ! 6. Спрессованная таблетка по любому из пп.1-3, которая включает более чем 250 и вплоть до 360 мг валсартана в качестве действующего вещества.
Claims (6)
1. Спрессованная таблетка, включающая валсартан в качестве действующего вещества и от 31 до 65% микрокристаллической целлюлозы в пересчете на общую массу компонентов ядра этой спрессованной таблетки.
2. Спрессованная таблетка по п.1, включающая от 50 до 65% микрокристаллической целлюлозы в пересчете на общую массу.
3. Спрессованная таблетка по п.1, включающая 50% микрокристаллической целлюлозы в пересчете на общую массу.
4. Спрессованная таблетка по любому из пп.1-3, включающая менее 13 мас.% кросповидона.
5. Спрессованная таблетка по любому из пп.1-3, в которой массовое отношение валсартана к микрокристаллической целлюлозе составляет от 2:1 до 1:1.
6. Спрессованная таблетка по любому из пп.1-3, которая включает более чем 250 и вплоть до 360 мг валсартана в качестве действующего вещества.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP98811258A EP1013273A1 (en) | 1998-12-23 | 1998-12-23 | Use of AT-1 receptor antagonist or AT-2 receptor modulator for treating diseases associated with an increase of AT-1 or AT-2 receptors |
| EP98811257 | 1998-12-23 | ||
| EP98811257.9 | 1998-12-23 | ||
| EP98811258.7 | 1998-12-23 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2005124363/15A Division RU2361575C2 (ru) | 1998-12-23 | 2005-08-01 | Твердые пероральные дозируемые формы валсартана |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2012157622/15A Division RU2012157622A (ru) | 2012-12-27 | 2012-12-27 | Применение антагониста рецептора ат-1 или модулятора рецептора ат-2 для лечения болезней, связанных с увеличением содержания рецепторов ат-1 или ат-2 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2008143545A true RU2008143545A (ru) | 2010-05-10 |
Family
ID=26152118
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2001119990/15A RU2271809C2 (ru) | 1998-12-23 | 1999-12-22 | Применение антагониста рецептора at-1 или модулятора рецептора ат-2 для лечения болезней, связанных с увеличением содержания рецепторов ат-1 или ат-2 |
| RU2005124363/15A RU2361575C2 (ru) | 1998-12-23 | 2005-08-01 | Твердые пероральные дозируемые формы валсартана |
| RU2008143545/15A RU2008143545A (ru) | 1998-12-23 | 2008-11-05 | Применение антагониста рецептора ат-1 или модулятора рецептора ат-2 для лечения болезней, связанных с увеличением содержания рецепторов ат-1 или ат-2 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2001119990/15A RU2271809C2 (ru) | 1998-12-23 | 1999-12-22 | Применение антагониста рецептора at-1 или модулятора рецептора ат-2 для лечения болезней, связанных с увеличением содержания рецепторов ат-1 или ат-2 |
| RU2005124363/15A RU2361575C2 (ru) | 1998-12-23 | 2005-08-01 | Твердые пероральные дозируемые формы валсартана |
Country Status (26)
| Country | Link |
|---|---|
| EP (3) | EP2298298A3 (ru) |
| JP (2) | JP2002533390A (ru) |
| KR (1) | KR100646716B1 (ru) |
| CN (2) | CN1304000C (ru) |
| AT (2) | ATE354364T1 (ru) |
| AU (4) | AU3043000A (ru) |
| BR (1) | BR9916576A (ru) |
| CA (2) | CA2622805C (ru) |
| CY (2) | CY1106581T1 (ru) |
| CZ (2) | CZ293257B6 (ru) |
| DE (1) | DE69935249T2 (ru) |
| DK (2) | DK1588706T3 (ru) |
| ES (2) | ES2373556T3 (ru) |
| HK (1) | HK1038888B (ru) |
| HU (1) | HUP0104780A3 (ru) |
| ID (1) | ID29856A (ru) |
| IL (5) | IL143233A0 (ru) |
| NO (2) | NO328775B1 (ru) |
| NZ (3) | NZ511938A (ru) |
| PL (1) | PL199100B1 (ru) |
| PT (2) | PT1140071E (ru) |
| RU (3) | RU2271809C2 (ru) |
| SI (2) | SI1588706T1 (ru) |
| SK (1) | SK9132001A3 (ru) |
| TR (7) | TR200805740T1 (ru) |
| WO (1) | WO2000038676A1 (ru) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100659644B1 (ko) * | 2000-06-22 | 2006-12-21 | 노파르티스 아게 | 고형 발사르탄 약제학적 조성물 |
| JP4972847B2 (ja) * | 2000-10-11 | 2012-07-11 | 住友化学株式会社 | コラーゲン蓄積抑制剤 |
| JPWO2002083127A1 (ja) * | 2001-04-09 | 2004-09-30 | 宮田 敏男 | 蛋白修飾物生成抑制組成物 |
| DK1395566T3 (da) | 2001-05-31 | 2008-01-07 | Vicore Pharma Ab | Tricycliske forbindelser, der er nyttige som angiotensin Il-agonister |
| US7812044B2 (en) | 2001-11-13 | 2010-10-12 | Takeda Pharmaceutical Company Limited | Anticancer agents |
| EG24716A (en) | 2002-05-17 | 2010-06-07 | Novartis Ag | Combination of organic compounds |
| EP1680095A2 (en) * | 2003-11-03 | 2006-07-19 | Zentiva, a.s. | Valsartan containing formulation |
| WO2006066961A1 (en) | 2004-12-24 | 2006-06-29 | Krka, D.D., Novo Mesto | Solid pharmaceutical composition comprising valsartan |
| CN102861019B (zh) * | 2004-12-24 | 2016-05-25 | 诺华股份有限公司 | 治疗或预防神经性疼痛的药物 |
| WO2006136916A2 (en) * | 2005-06-20 | 2006-12-28 | Glenmark Pharmaceuticals Limited | Substantially pure micronized particles of telmisartan and pharmaceutical compositions containing same |
| GT200600371A (es) | 2005-08-17 | 2007-03-21 | Formas de dosis sólidas de valsartan y amlodipina y método para hacer las mismas | |
| ES2246742B1 (es) * | 2005-09-06 | 2007-02-01 | Prous Institute For Biomedical Research S.A. | Uso de un derivado de imidazol. |
| US8080534B2 (en) | 2005-10-14 | 2011-12-20 | Phigenix, Inc | Targeting PAX2 for the treatment of breast cancer |
| WO2008120242A1 (en) * | 2007-03-29 | 2008-10-09 | Alembic Limited | Valsartan tablet formulations |
| TR200703568A1 (tr) | 2007-05-24 | 2008-07-21 | Sanovel �La� Sanay� Ve T�Caret Anon�M ��Rket� | Valsartan formülasyonları |
| CA2701695A1 (en) | 2007-10-09 | 2009-04-16 | Novartis Ag | Pharmaceutical formulation of valsartan |
| EP3067043B1 (en) * | 2007-11-06 | 2022-11-30 | Novartis AG | Pharmaceutical compositions based on superstructures of angiotensin receptor antagonist/blocker (arb) and neutral endopeptidase (nep) inhibitor |
| US20110104166A1 (en) | 2008-01-18 | 2011-05-05 | Stankovic Konstantina M | Methods and Compositions for Treating Polyps |
| GB0802931D0 (en) * | 2008-02-18 | 2008-03-26 | Queen Mary & Westfield College | Synthetic scFv analogue to the 6313/G2 (anti angiotensin II type 1 receptor) monoclonal anitbody variable regions |
| EP2405899A2 (en) | 2009-03-11 | 2012-01-18 | Sanovel Ilaç Sanayi Ve Ticaret Anonim Sirketi | Valsartan formulations |
| WO2011102702A2 (en) | 2010-02-16 | 2011-08-25 | Krka, D. D., Novo Mesto | Process for the preparation of oral solid dosage forms comprising valsartan |
| EP2455388A1 (en) | 2010-11-23 | 2012-05-23 | LanthioPep B.V. | Novel angiotensin type 2 (AT2) receptor agonists and uses thereof. |
| CN102266307B (zh) * | 2011-08-01 | 2012-10-24 | 海南锦瑞制药股份有限公司 | 一种缬沙坦胶囊及其制备方法 |
| WO2013098578A1 (en) | 2011-12-31 | 2013-07-04 | Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi | Immediate release pharmaceutical composition of valsartan hydrochlorothiazide |
| WO2013098576A1 (en) | 2011-12-31 | 2013-07-04 | Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi | Immediate release pharmaceutical composition of valsartan |
| EA018867B1 (ru) * | 2012-11-01 | 2013-11-29 | Лаборатория Тютор С.А.С.И.Ф.И.А. | Способ получения фармацевтической композиции и продукт способа |
| WO2021023698A1 (en) | 2019-08-02 | 2021-02-11 | Lanthiopep B.V | Angiotensin type 2 (at2) receptor agonists for use in the treatment of cancer |
| EP4295839A1 (en) | 2022-06-20 | 2023-12-27 | KRKA, d.d., Novo mesto | Combination of valsartan and indapamide |
| WO2024026528A1 (en) * | 2022-08-02 | 2024-02-08 | Dimerix Bioscience Pty Ltd | Dosage regimen for the treatment of copd |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3146168A (en) | 1962-04-10 | 1964-08-25 | Fmc Corp | Manufacture of pharmaceutical preparations containing cellulose crystallite aggregates |
| CA1334092C (en) | 1986-07-11 | 1995-01-24 | David John Carini | Angiotensin ii receptor blocking imidazoles |
| EP0330284B1 (en) * | 1988-02-25 | 1994-07-27 | Yamanouchi Europe B.V. | Process for the preparation of a pharmaceutical granulate |
| ATE190051T1 (de) | 1989-06-14 | 2000-03-15 | Smithkline Beecham Corp | Imidazoalkensäure |
| IE70593B1 (en) | 1989-09-29 | 1996-12-11 | Eisai Co Ltd | Biphenylmethane derivative the use of it and pharmacological compositions containing same |
| DE122007000050I1 (de) * | 1990-02-19 | 2007-11-08 | Novartis Ag | Acylverbindungen |
| PT97078B (pt) | 1990-03-20 | 1997-07-31 | Sanofi Sa | Processo para a preparacao de derivados heterociclicos n-substituidos e de composicoes farmaceuticas que os contem |
| US5196444A (en) | 1990-04-27 | 1993-03-23 | Takeda Chemical Industries, Ltd. | 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof |
| IL99246A0 (en) | 1990-09-10 | 1992-07-15 | Abbott Lab | Angiotensin ii receptor antagonists and pharmaceutical compositions containing them |
| EP0551432A1 (en) * | 1990-10-02 | 1993-07-21 | Warner-Lambert Company | 4,5,6,7-tetrahydro-1h-imidazo 4,5-c]pyridine derivatives and analogues as angiotensin ii receptor antagonists |
| DE4038335A1 (de) * | 1990-12-01 | 1992-06-04 | Boehringer Mannheim Gmbh | Neue pyridinderivate, verfahren zu ihrer herstellung und verwendung als arzneimittel |
| SI9210098B (sl) | 1991-02-06 | 2000-06-30 | Dr. Karl Thomae | Benzimidazoli, zdravila, ki te spojine vsebujejo, in postopek za njihovo pripravo |
| US5614519A (en) * | 1991-02-06 | 1997-03-25 | Karl Thomae Gmbh | (1-(2,3 or 4-N-morpholinoalkyl)-imidazol-4-yl)-benizimidazol-1-yl-methyl]-biphenyls useful as angiotensin-II antagonists |
| US5196537A (en) | 1991-03-21 | 1993-03-23 | G. D. Searle & Co. | 5-apylheteroarylalkyl-1,3,5-trisubstituted-1,2,4-triazole compounds for treatment of circulatory disorders |
| GB9110636D0 (en) | 1991-05-16 | 1991-07-03 | Glaxo Group Ltd | Chemical compounds |
| DE4132632A1 (de) * | 1991-10-01 | 1993-04-08 | Bayer Ag | Substituierte imidazolyl-propensaeurederivate |
| DE4309968A1 (de) * | 1993-03-26 | 1994-09-29 | Bayer Ag | Phenylglycinamide von heterocyclisch substituierten Phenylessigsäurederivaten |
| DK0636027T3 (da) | 1992-04-13 | 2000-01-31 | Zeneca Ltd | Angiotensin-II-antogonister mod sygdomme forbundet med forringet neuronal ledningshastighed, især diabetisk neuropati |
| US5246943A (en) * | 1992-05-19 | 1993-09-21 | Warner-Lambert Company | Substituted 1,2,3,4-tetahydroisoquinolines with angiotensin II receptor antagonist properties |
| CA2151384A1 (en) | 1992-12-11 | 1994-06-23 | Peter Buhlmayer | Benzazepinone derivatives |
| HUT71557A (en) * | 1992-12-11 | 1995-12-28 | Ciba Geigy Ag | Substituted benzazepinones, process for producing them and pharmaceutical compositions containing them |
| DE4309963A1 (de) * | 1993-03-26 | 1994-09-29 | Hubert Kamperschroer | Faß zum Austragen von Gülle |
| FR2716882B1 (fr) * | 1994-03-04 | 1996-04-05 | Roussel Uclaf | Utilisation de dérivés de l'imidazole au traitement d'affections impliquant les récepteurs AT1 et AT2 de l'Angiotensine, certains de ces produits, leur préparation, compositions pharmaceutiques. |
| DE4408497A1 (de) * | 1994-03-14 | 1995-09-21 | Thomae Gmbh Dr K | Benzimidazole, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
| AU1850695A (en) * | 1994-03-17 | 1995-10-03 | Novartis Ag | Treatment of diabetic nephropathy with valsartan |
| DE4432860A1 (de) * | 1994-09-15 | 1996-03-21 | Merck Patent Gmbh | Imidazopyridine |
| PT853477E (pt) | 1995-10-06 | 2003-01-31 | Novartis Ag | Antagonistas de receptores at1 para prevencao e tratamento de insuficiencia renal pos-isquemica e para proteccao de rim isquemico |
| WO1997031624A1 (en) | 1996-02-27 | 1997-09-04 | Purdue Research Foundation | Liposomal delivery system |
| US6174910B1 (en) * | 1996-02-29 | 2001-01-16 | Novartis Ag | AT1 receptor antagonist for the stimulation of apoptosis |
| GB9613470D0 (en) * | 1996-06-27 | 1996-08-28 | Ciba Geigy Ag | Small solid oral dosage form |
| DE19628617A1 (de) * | 1996-07-16 | 1998-01-22 | Basf Ag | Direkttablettierhilfsmittel |
| PT1096932E (pt) * | 1998-07-10 | 2007-09-21 | Novartis Pharma Ag | ''combinação anti-hipertensiva de valsartan e bloqueadores do canal de cálcio'' |
| DK1146872T3 (da) | 1999-01-26 | 2006-10-16 | Novartis Ag | Anvendelse af angiotensin II-receptorantagonister til behandling af akut myokardieinfarkt |
| KR100659644B1 (ko) * | 2000-06-22 | 2006-12-21 | 노파르티스 아게 | 고형 발사르탄 약제학적 조성물 |
| WO2005039637A2 (en) | 2003-10-17 | 2005-05-06 | Novartis Ag | Combinations of an aldosterone receptor antagonist, a diuretic and an angiotensin blocker |
| JP2009018990A (ja) | 2005-10-25 | 2009-01-29 | Univ Kurume | Ｃ型肝炎ウイルス由来ペプチド |
-
1999
- 1999-12-22 EP EP10010334A patent/EP2298298A3/en not_active Withdrawn
- 1999-12-22 NZ NZ511938A patent/NZ511938A/xx not_active IP Right Cessation
- 1999-12-22 WO PCT/EP1999/010330 patent/WO2000038676A1/en not_active Ceased
- 1999-12-22 BR BR9916576-7A patent/BR9916576A/pt not_active IP Right Cessation
- 1999-12-22 EP EP05013209A patent/EP1588706B1/en not_active Revoked
- 1999-12-22 SK SK913-2001A patent/SK9132001A3/sk unknown
- 1999-12-22 DK DK05013209.1T patent/DK1588706T3/da active
- 1999-12-22 ES ES05013209T patent/ES2373556T3/es not_active Expired - Lifetime
- 1999-12-22 TR TR2008/05740T patent/TR200805740T1/xx unknown
- 1999-12-22 JP JP2000590630A patent/JP2002533390A/ja not_active Withdrawn
- 1999-12-22 DK DK99964665T patent/DK1140071T3/da active
- 1999-12-22 NZ NZ553010A patent/NZ553010A/en not_active IP Right Cessation
- 1999-12-22 KR KR1020017007996A patent/KR100646716B1/ko not_active Expired - Fee Related
- 1999-12-22 ES ES99964665T patent/ES2281978T3/es not_active Expired - Lifetime
- 1999-12-22 HK HK02100661.6A patent/HK1038888B/en not_active IP Right Cessation
- 1999-12-22 IL IL14323399A patent/IL143233A0/xx not_active IP Right Cessation
- 1999-12-22 PT PT99964665T patent/PT1140071E/pt unknown
- 1999-12-22 TR TR2006/05472T patent/TR200605472T1/xx unknown
- 1999-12-22 CZ CZ20012306A patent/CZ293257B6/cs not_active IP Right Cessation
- 1999-12-22 TR TR2006/05471T patent/TR200605471T2/xx unknown
- 1999-12-22 NZ NZ587909A patent/NZ587909A/en not_active IP Right Cessation
- 1999-12-22 CN CNB998150452A patent/CN1304000C/zh not_active Expired - Fee Related
- 1999-12-22 PL PL349424A patent/PL199100B1/pl not_active IP Right Cessation
- 1999-12-22 TR TR2002/00764T patent/TR200200764T2/xx unknown
- 1999-12-22 RU RU2001119990/15A patent/RU2271809C2/ru not_active IP Right Cessation
- 1999-12-22 ID IDW00200101299Q patent/ID29856A/id unknown
- 1999-12-22 SI SI9931064T patent/SI1588706T1/sl unknown
- 1999-12-22 TR TR2008/05741T patent/TR200805741T2/xx unknown
- 1999-12-22 CA CA2622805A patent/CA2622805C/en not_active Expired - Fee Related
- 1999-12-22 AT AT99964665T patent/ATE354364T1/de not_active IP Right Cessation
- 1999-12-22 AT AT05013209T patent/ATE524176T1/de active
- 1999-12-22 PT PT05013209T patent/PT1588706E/pt unknown
- 1999-12-22 AU AU30430/00A patent/AU3043000A/en not_active Abandoned
- 1999-12-22 TR TR2001/01784T patent/TR200101784T2/xx unknown
- 1999-12-22 CZ CZ20032559A patent/CZ297795B6/cs not_active IP Right Cessation
- 1999-12-22 CA CA002351357A patent/CA2351357A1/en not_active Abandoned
- 1999-12-22 CN CNA200410087973XA patent/CN1636561A/zh active Pending
- 1999-12-22 HU HU0104780A patent/HUP0104780A3/hu unknown
- 1999-12-22 TR TR2008/05275T patent/TR200805275T2/xx unknown
- 1999-12-22 EP EP99964665A patent/EP1140071B1/en not_active Revoked
- 1999-12-22 SI SI9930963T patent/SI1140071T1/sl unknown
- 1999-12-22 DE DE69935249T patent/DE69935249T2/de not_active Revoked
-
2001
- 2001-05-17 IL IL143233A patent/IL143233A/en not_active IP Right Cessation
- 2001-06-22 NO NO20013143A patent/NO328775B1/no not_active IP Right Cessation
-
2003
- 2003-12-02 AU AU2003266433A patent/AU2003266433B2/en not_active Ceased
-
2005
- 2005-08-01 RU RU2005124363/15A patent/RU2361575C2/ru not_active IP Right Cessation
-
2006
- 2006-07-18 AU AU2006203077A patent/AU2006203077B2/en not_active Expired
- 2006-11-02 IL IL179016A patent/IL179016A0/en unknown
- 2006-11-02 IL IL179017A patent/IL179017A0/en unknown
- 2006-11-02 IL IL179015A patent/IL179015A0/en unknown
-
2007
- 2007-05-10 CY CY20071100642T patent/CY1106581T1/el unknown
-
2008
- 2008-11-05 RU RU2008143545/15A patent/RU2008143545A/ru unknown
-
2009
- 2009-09-24 AU AU2009220022A patent/AU2009220022B2/en not_active Expired
-
2010
- 2010-01-12 NO NO20100041A patent/NO20100041L/no not_active Application Discontinuation
- 2010-01-18 JP JP2010008140A patent/JP5254258B2/ja not_active Expired - Lifetime
-
2011
- 2011-12-06 CY CY20111101213T patent/CY1112395T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2008143545A (ru) | Применение антагониста рецептора ат-1 или модулятора рецептора ат-2 для лечения болезней, связанных с увеличением содержания рецепторов ат-1 или ат-2 | |
| MY123149A (en) | Solid oral dosage forms of valsartan | |
| UY24308A1 (es) | Tabletas exentas de aglutinante que contienen tramadol o una sal de tramadol, para administracion oral | |
| ATE260646T1 (de) | Schnell zerfallende orale dosierungsform | |
| TR200001942T2 (tr) | Opioid agonist/antagonist kombinasyonlar | |
| UA66750C2 (en) | Substituted 1-phenylpirazole 3-carboxamides, a method for the preparation thereof and intermediary compounds, pharmaceutical composition having affinity to neurotensin receptors | |
| ATE371645T1 (de) | Naphthalinderivate, die sich an den ep4?rezeptor binden | |
| EA200000487A1 (ru) | Композиция пролонгированного высвобождения | |
| CA2325739A1 (en) | Combination for the treatment of alcohol and drug dependence containing an opioid antagonist and a nmda receptor complex modulator | |
| EA200200207A1 (ru) | Применение антагонистов cgrp и ингибиторов высвобождения cgrp для устранения приливов в период менопаузы | |
| TW324662B (en) | Benzamide-containing pharmaceutical composition | |
| MY135916A (en) | Use of certain affinity nmda antagonists as antidepressants | |
| PL371963A1 (en) | Pharmaceutical composition comprising n- ((1-n-butyl-4-piperidinyl) methyl)-3, 4-dihydro-2h- (1, 3) oxazino (3, 2-a) indole-10-carboxamide or salt and process therefor comprising dry granulation | |
| TW200518785A (en) | Pharmaceutical formulation | |
| PT975348E (pt) | Composicoes de tibolona estabilizadas | |
| EA200100947A1 (ru) | Жевательные таблетки с высоким содержанием n-ацетилцистеина | |
| ES2195010T3 (es) | Derivados de di-arilalquenilaminas. | |
| FR2845378B1 (fr) | Base fumigene et utilisations | |
| TR199701617T1 (xx) | �iftliklerde �retilen bal�klarda g�r�len parazitlerle m�cadelede kullan�lacak bir ajan. | |
| UA37217C2 (ru) | Аналоги 15-дезоксиспергуалина, способ их получения, фармацевтическая композиция и промежуточные соединения | |
| ATE227981T1 (de) | Captopriltabletten | |
| ATE242224T1 (de) | Fungizide aza-heterocycloalkene | |
| BG102638A (bg) | Таблети с високо съдържание на фамцикловир | |
| NO20056220L (no) | Derimiciklane fumerat-tabletter | |
| DE3778165D1 (ru) |